Reynolds J C, Del Vecchio S, Sakahara H, Lora M E, Carrasquillo J A, Neumann R D, Larson S M
Nuclear Medicine Department, National Institutes of Health, Bethesda, MD 20892.
Int J Rad Appl Instrum B. 1989;16(2):121-5. doi: 10.1016/0883-2897(89)90182-7.
Many patients given murine monoclonal antibody become immune to these proteins. Important factors in the development of immunity are (1) the patient's ability to become immune and (2) whether whole immunoglobulin or Fab fragment was used. Circulating anti-murine antibodies increase the murine antibody plasma clearance and the liver or spleen uptake while reducing tumor targeting. Clearance rates and radioassay measured levels of anti-murine antibodies are related to serum murine/anti-murine antibody complexes. Unlabeled murine antibody displaces radiolabeled antibody from these complexes.
许多接受鼠源单克隆抗体治疗的患者会对这些蛋白质产生免疫反应。免疫反应发生的重要因素包括：（1）患者产生免疫的能力；（2）使用的是完整免疫球蛋白还是Fab片段。循环中的抗鼠抗体增加了鼠源抗体的血浆清除率以及肝脏或脾脏摄取量，同时降低了肿瘤靶向性。抗鼠抗体的清除率和放射分析测量水平与血清鼠源/抗鼠抗体复合物有关。未标记的鼠源抗体可从这些复合物中置换出放射性标记的抗体。
